SciELO - Scientific Electronic Library Online

 
vol.34 issue2Thirty years of the Oncological Urology Work Group of the Spanish Association of Urology (1978-2008) author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Actas Urológicas Españolas

Print version ISSN 0210-4806

Abstract

SANCHEZ ZALABARDO, D.; MILLAN SERRANO, J. A.; PABLO CARDENAS, Á. De  and  CUESTA ALCALA, J. Á.. Treatment of locally advanced renal tumors. Actas Urol Esp [online]. 2010, vol.34, n.2, pp.134-141. ISSN 0210-4806.

Introduction: Locally advanced renal tumors show a high progression rate after surgery. Surgical treatment of renal tumors has some unique characteristics related to involvement of the adrenal gland, vena cava, or regional lymph nodes. Objective: To review the current treatment of locally advanced renal tumors. Materials and methods: A review is made of both the different drugs used and the different therapeutic possibilities in these tumors. Results: Systemic treatment with angiogenesis inhibitors may improve the natural history of these patients. Systemic treatment may be administered before surgery or as an adjuvant to surgical treatment. Early studies showed a decrease in tumor mass when treatment is administered before surgery, but no prospective randomized studies providing adequate evidence for recommending neoadjuvant treatment are available. Conclusions: Availability of systemic treatment with angiogenesis inhibitors may open an important field in the treatment of these tumors in both the neoadjuvant setting and as adjuvants to surgery, but no sufficiently solid scientific evidence as to recommend their use is currently available. Randomized studies with sunitinib and sorafenib will probably suggest the adequate approach to be used when their final results are reported.

Keywords : Locally advanced renal tumor; Treatment; Tyrosine kinase inhibitors; Sunitinib; Sorafenib; Tersirolimus; Bevacizumab.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License